Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma

BACKGROUND: Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated predictive biomarkers for sorafenib. Our purpose was to determine if sorafenib target expression is predictive of sorafenib sensitivity....

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Aziz, Saadia A, Sznol, Joshua A, Albiges, Laurence, Zito, Christopher, Jilaveanu, Lucia B, Camp, Robert L, Escudier, Bernard, Kluger, Harriet M
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2014
Matèries:
Primary Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3896780/
https://ncbi.nlm.nih.gov/pubmed/24423208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-14-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars